Peer-Reviewed Studies Supporting PACVS Biology

This page presents referenced scientific literature that supports the biological mechanisms and clinical understanding of Post-Acute COVID-19 Vaccine Syndrome (PACVS). The selected studies explore spike protein persistence, immune and mitochondrial dysfunction, autoantibody activity, and related physiological disruptions.

This content is updated as new peer-reviewed literature and functional diagnostic insights become available to support the understanding of PACVS. If you wish to contribute to the scientific evidence list, please contact us.

Peer-reviewed evidence list last updated on July 9, 2026

Spike Protein Persistence and Pathogenicity

This section features peer-reviewed studies demonstrating that SARS-CoV-2 spike protein can persist in the body long after infection or mRNA vaccination. These studies explore how lingering spike protein – circulating in plasma, exosomes, or tissues – may trigger immune activation, cellular stress, and chronic symptoms.

Autoantibodies and Immune Dysregulation

The following studies examine vaccine-associated immune dysregulation, particularly the development of autoantibodies targeting GPCRs, ACE2, β-adrenergic, and muscarinic receptors. This autoimmune activity has been linked to PACVS symptoms such as dysautonomia, chronic fatigue, POTS, and vascular inflammation. Other studies explore broader immune changes post-vaccination, including antibody subclass switching and altered effector functions.

Mitochondrial Dysfunction

These studies explore how the SARS-CoV-2 spike protein and chronic immune activation can impair mitochondrial function. Mechanisms include reduced ATP production, oxidative stress, and mitochondrial fragmentation – all of which are relevant to the fatigue and post-exertional malaise seen in PACVS.

Gut Dysbiosis and Permeability

This section presents evidence that gut microbiota imbalance and increased intestinal permeability may play a role in vaccine response and PACVS. The gut-brain-immune axis is increasingly recognized as a driver of chronic inflammation, autoimmunity, and post-vaccine symptomatology.

Autonomic and Parasympathetic Dysfunction

These peer-reviewed studies detail how COVID-19 vaccination may trigger autonomic nervous system dysfunction, including POTS, sympathetic overactivation, and parasympathetic dysregulation. Symptoms such as tachycardia, dizziness, and cognitive fatigue are common in PACVS patients.

Cardiac Injury

This section includes studies on myocarditis, pericarditis, and cardiac inflammation following mRNA COVID-19 vaccination. It covers autopsy findings, clinical follow-up, and population-based risk assessments, providing essential evidence for understanding PACVS-related cardiac effects.

Vascular and Endothelial Dysfunction

Here we highlight research on vascular inflammation, endothelial damage, and microthrombi associated with COVID-19 and vaccination. These studies support the theory that spike protein and immune activation may contribute to ongoing vascular complications in PACVS.

  • Yamada S et al., 2022 — Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
    https://doi.org/10.3390/ijms23063338
  • Chang JC et al., 2021 — Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis
    https://doi.org/10.3390/medicina57111163
  • Civieri G et al., 2022 — Antibodies Against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies
    https://doi.org/10.3390/ijms23020927
  • Chatterjee B et al., 2024 — Moderate Elevation of Homocysteine Induces Endothelial Dysfunction Through Adaptive UPR Activation and Metabolic Rewiring
    https://doi.org/10.3390/cells13030214
  • Hiemann NE et al., 2012 — Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation.
    https://doi.org/10.1097/TP.0b013e3182692ad2
  • Kadiyska T et al., 2022 — Role of endothelial dysfunction in the severity of COVID-19 infection (Review). Molecular Medicine Reports.
    https://doi.org/10.3892/mmr.2022.12867
  • Castro‑Robles B et al., 2024 — Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID‑19 booster vaccine are associated with spike‑specific IgG antibody production.
    https://doi.org/10.3389/fimmu.2024.1471401
  • Devaux CA et al., 2023 — Molecular mimicry of the viral spike in the SARS-CoV-2 vaccine possibly triggers transient dysregulation of ACE2, leading to vascular and coagulation dysfunction similar to SARS-CoV-2 infection.
    https://doi.org/10.3390/v15051045
  • Waters M et al., 2026 — Proteomic signatures of COVID-19 Post-Vaccination/Post-Infection Syndrome (PV/PIS): insights into immune dysregulation and coagulopathy. Frontiers in Cellular and Infection Microbiology.
    https://doi.org/10.3389/fcimb.2026.1753348
  • Know a new peer-reviewed study we should include? Contact Us!

Plasmid DNA, mRNA, and Genetic Persistence

This section includes peer-reviewed research on residual plasmid DNA, SV40 enhancer sequences, and mRNA-related persistence in COVID-19 vaccines. These findings raise important questions about biodistribution, transcriptional activity, and long-term biological effects.

  • Kammerer J et al., 2024 — Plasmid DNA contamination in COVID-19 vaccines. Science, Public Health Policy & the Law.
    https://publichealthpolicyjournal.com/wp-content/uploads/2025/02/KammererEtAl_SciencePublicHealthPolicyAndTheLaw_v5.2019-2024.Dec_2024.pdf
  • Krawczyk PS et al., 2025 — Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.
    This Nature study shows that after mRNA vaccination, immune cells begin expressing the enzyme TENT5A, which modifies the vaccine mRNA by extending its poly(A) tail. This increases the stability and lifespan of the synthetic mRNA inside cells, potentially prolonging spike protein production well beyond initial expectations. The effect was strongest with Moderna’s mRNA-1273, but also present with Pfizer’s BNT162b2. These findings raise important questions about mRNA persistence, immune cell programming, and chronic immune activation in PACVS.
    https://doi.org/10.1038/s41586-025-08842-1
  • Igyártó BZ, Qin Z, 2024 — The mRNA-LNP vaccines – the good, the bad and the ugly
    https://doi.org/10.3389/fimmu.2024.1336906
  • du Preez HN et al., 2024 — COVID-19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy.
    https://doi.org/10.1111/eci.14296
  • Pateev I et al., 2023 — Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies.
    https://doi.org/10.3390/biomedicines12010059
  • Speicher DJ et al., 2025 — Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada. Autoimmunity.
    https://doi.org/10.1080/08916934.2025.2551517
  • Hulscher N et al., 2026 — Persistence of Vaccine mRNA, Plasmid DNA, Spike Protein, and Genomic Dysregulation Over 3.5 Years Post-COVID-19 mRNA Vaccination. European Society of Medicine.
    https://doi.org/10.18103/mra.2026.0351
  • Know a new peer-reviewed study we should include? Contact Us!

Serological Differentiation: Vaccine vs Natural Infection

This section presents peer-reviewed studies investigating the differences in antibody responses after COVID-19 vaccination compared to natural infection. Understanding these serological signatures provides important tools for distinguishing PACVS from post-viral syndromes and validating vaccine-specific biological effects.